



JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :
Kaesemeyer :
Serial No. 10/763,309 : Group Art Unit: 1614
Filed: January 23, 2004 : Examiner: not yet assigned

For: PHARMACEUTICAL COMPOSITION COMPRISING CITRULLINE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Mail Stop DD
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to deposit account no. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP



Raymond A. Miller
Registration No. 42,891

Pepper Hamilton LLP
One Mellon Bank Center
50th Floor
500 Grant Street
Pittsburgh, PA 15219
Telephone: (412) 454-5813
Facsimile: (412) 281-0717
Date: September 29, 2004



Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

				Complete if Known	
				Application Number	10/763,309
				Filing Date	January 23, 2004
				First Named Inventor	Kaesemeyer
				Group Art Unit	1614
				Examiner Name	Not yet assigned
Sheet	1	of 2		Attorney Docket Number	126625.801

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
		5,595,970		Garfield et al.	01-21-1997	
		5,665,077		Rosen et al.	09-09-1997	
		5,482,925		Hutsell	01-09-1996	
		5,405,919		Keefer et al.	04-11-1995	
		5,543,430		Kaesemeyer	08-06-1996	
		5,767,160		Kaesemeyer	06-16-1998	
		4,857,522		DiPietro et al.	08-15-1989	
		5,190,970		Pan et al.	03-02-1993	
		5,461,039		Tschollar et al.	10-24-1995	
		5,316,765		Folkers et al.	05-31-1994	
		4,920,098		Cotter et al.	04-24-1990	
		5,106,836		Clemens et al.	04-21-1992	
		5,171,217		March et al.	12-15-1992	
		5,278,189		Rath et al.	01-11-1994	
		5,428,070		Cooke et al.	06-27-1995	
		5,650,418		Rath et al.	07-22-1997	
		5,852,058		Cooke et al.	12-22-1998	
		5,861,168		Cooke et al.	01-19-1999	
		5,891,459		Cooke et al.	04-06-1999	

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
		WO	92/11895		Boston Scientific Corp.	07-23-1992		
		WO	95/05866		Cortrak Medical, Inc.	03-12-1995		
		WO	96/08286		Local Med, Inc.	03-21-1996		
		WO	84/02131		Sandoz AG	06-07-1984		
		EP	0546796	A1	Ajinomoto Co., Inc.	06-16-1993		

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known		
				Application Number		10/763,309
				Filing Date		January 23, 2004
				First Named Inventor		Kaesemeyer
				Group Art Unit		1614
				Examiner Name		Not yet assigned
Sheet	2	of 2		Attorney Docket Number	126625.801	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
Examiner's Initials	Cite No.				T	
		Ignarro, Louis J, PhD., 1991, Pharmacology of Endothelium-Derived Nitric Oxide and Nitrovasodilators, The Western Journal of Medicine, pp. 51-62.				
		Stewart, D.D., 1888, Remarkable Tolerance to Nitroglycerin, Philadelphia Polyclinic, 172-5.				
		Freelisch et al., Biochem. and Biophys. Res. Comm. 1991: 180, No 1: 286-293.				
		Sunderkotter, et al., J. Leukoc. Biol. 1994 Mar, 55(3)L 410-22.				
		Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton PA)				
		Chester, Adrian H. et al., Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. The Lancet, Vol. 336.				
		Wolf, Yelinda G. et al., Nitroglycerin decreases medial smooth muscle cell proliferation after arterial balloon injury, Journal of Vascular Surgery, March 1995, p. 499-503.				
		Harrison, David G., Endothelial Modulation of Vascular Tone: Relevance to Coronary Angioplasty and Restenosis, JACC, Vol. 17, No. 6, May 1991, p. 71B-76B.				
		Feldman, M. et al., Microfabricated Device for Intravascular Delivery, JACC, February 1998, p. 351A.				
		Ra, K. et al., JPET, 1982, 221: 525-531.				
		Draper, NJ et al., Contrasting Effect of NO Synthase Inhibition on LV Function During Early and Late Reoxygenation, Heart, p. 187.*				
		Niebauer, et al., Local L-Arginine Delivery After Balloon Angioplasty Reduces Monocyte Binding and Induces Apoptosis, Division of Cardiovascular Medicine, Stanford University, 1999 American Heart Association, Inc., 1830-1835.				
Examiner Signature			Date Considered			

*reference not available at this time, will provide in a supplemental filing

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

APPLICANT:

KAESEMEYER

TITLE:

PHARMACEUTICAL COMPOSITION COMPRISING
CITRULLING

SERIAL NO.

10/763,309

ATTORNEY REF:

126625.00801


DATE OF DEPOSIT:

September 29, 2004

I HEREBY CERTIFY THAT THIS INFORMATION DISCLOSURE STATEMENT
TOGETHER WITH THE DOCUMENTS CITED THEREIN IS BEING DEPOSITED WITH
THE UNITED STATES POSTAL SERVICE VIA FIRST CLASS MAIL UNDER 37 CFR 1.10
ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO COMMISSIONER FOR
PATENTS, MAIL STOP DD, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Jennifer Martinez

(Typed or printed name of person mailing paper or fee)



Documents Enclosed:

1. Information Disclosure Statement
2. Cited References
3. Certificate of Mailing;
4. Postcard.